

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug production and registration for Calcium Gluconate and Sodium Chloride Injection (100ml:1g/0.8g) from National Medical Products Administration of China (the “NMPA”), being under type 3 chemical drug and regarded as passing the consistency evaluation. Calcium Gluconate and Sodium Chloride Injection is mainly used for the treatment of acute hypocalcemia, magnesium poisoning and fluoride poisoning, and has formed a calcium preparation product series together with the Group’s Calcium Gluconate and Sodium Chloride Injection (100ml:2g/675mg) approved on 4 June 2025 and Calcium Gluconate Injection (10ml:1g) approved on 18 July 2025.

The Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Morinidazole and Sodium Chloride Injection (100ml:0.5g/0.9g) from the NMPA, being under type 4 chemical drug and regarded as passing the consistency evaluation. Morinidazole and Sodium Chloride Injection is mainly used for adults in gynecological pelvic inflammatory diseases (including endometritis, salpingitis, tubo-ovarian abscess, pelvic peritonitis, etc.) and in combined surgical treatment of suppurative appendicitis and gangrenous appendicitis, which all are caused by susceptible bacteria. As stated in the Company’s announcement dated 19 August 2025, the Group’s Morinidazole bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 15 September 2025

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.